Member Info for rebarm

How individuals voted is a personal matter unless they choose to disclose it.

What is more important is that a few.....only 5.........shareholders got off their backsides and made an effort to attend the AGM. Not for the refreshments, but for the opportunity to ask questions and discuss topics of concern. Were we in receipt of 'inside information'? No, of course not, but an open debate with a group of IMM players including scientists is a lot more fruitful than sitting behind a keyboard sniping.

A suggestion might be that instead of this constant whining and criticism based on limited/no knowledge of what's going on that more PIs should check out Google maps and find their way to London for next year's AGM and then ask questions directly of IMM management. Do bear in mind though that the trip would not be worth it solely for the refreshments!!

Not at all disgraceful!!

What was said in the interview in Feb was clearly restated at the AGM in June. News by year end of patent filing and deal. That's before 31st Dec 2025 so still 4.5 months to run

Whilst I appreciate Tim is the Master of Spin, investing/punting in the biotech sector does require a degree of patience.

Chill!!

Thanks. Got it!

Thanks Vas for the ongoing news flow.

Progress for sure but what a convoluted process! Sustainability and Social Value one such example. Yes, all very important but let's get the NHS sorted as the priority!

One concern that you might be able to help with. Under Product Categories the Digital Diagnostics Solutions product list does not include FDBK. Surely Bleepa is a key component?

Anybody have SA's email address? Thanks

Many thanks Vas. I don't live in London anymore or, for that matter, in the UK so somewhat out of tough with what is happening behind the scenes.

Looking through your post and links of 19:26, perhaps NCL's plan is not so far fetched in terms of timescales. It looks as though many of the building blocks are in place and being used actively albeit many with limited interaction. It just needs the 'glue' to join the pieces

Thanks Vas, another good document and seems excellent progress with NCL planning..........as long as it includes Bleepa.

However, it does highlight what i still feel is the biggest problem within the NHS and that is lack of joined-up thinking.

Yesterday you posted a link to the NCL Digital Diagnostics 5 Year Plan and my question/concern is why are they doing their own thing? Why isn't there a London 5 Year Plan? If NCL steam ahead and implement digital diagnostics for their area and other London ICBs do likewise with their own ideas then we will end up with a total mishmash of systems that when the need arises, and it will, to interact at some level between ICBs this will result in yet more cost and, potentially, an unwieldy system.

It is not necessary to replicate, duplicate, re-invent the wheel, whatever you want to call it, when requirements are similar across the country and both NHS practitioners and patients are crying out for improved communications

Masterblast

Good of you to drop by with your pearls of wisdom. However, I'll stick to minding/managing my own business and would urge you to consider the same with yours

Span,

Ref your post 16:04, 'Tim saying Avion deal alive, so meaning Avion conducting trial, that's not what he said in interview.' Let's be clear, Tim saying Avion deal alive does not mean Avion conducting trial. According to Tim, Avion are still in with their Lupazor/P140 $25m trial fund. However, in response to my question about Avion, he did appear a little less confident in his response than with others.

Turn the clock back to April 2018 and the P3 trial failure. Tim acknowledged at the AGM that this failure was entirely down to IMM. My interpretation of his explanation is that the trial failure was simply down to wrong dosage, wrong cohort profiling and an assumption that P140 (at the time) was a panacea for the treatment of SLE. Check-out the symptoms of SLE and the difficulty in diagnosis thereof and it is fairly obvious that one size does not fit all. To me, this admission from Tim to a live audience was quite astonishing given his reputation for smooth talking, detail light delivery.

It is clear that there has been a delay in the Avion lupus trial but reasons for that delay are now clearer given the further information about the P140 research and, to me, make perfect sense. The research conducted by Immupharma Bordeaux over the last 18 months has not only provided great value for the treatment of autoimmune indications but also the diagnosis. It is these findings which are being factored into the P140 trial for SLE and which, as a consequence, will result in a stronger trial less likely to fail.

Span again in post of 13th 17:19 claimed, 'I think Tim alluding to nothing near term and lanstead if they selling will drive sp back into 1's' Tim was not alluding or stating nothing in the near term!! Let me reiterate what has been said by other attendees. Before the 31st Dec 2025, so within the next 6 months, IMM will deliver on 2 fronts:

1. Patent filing which will cover new discoveries and, as a consequence, make a licence agreement with IMM for P140 that much more attractive.

2. A deal. No details on what that might look like but could I suppose be an exclusive licence for P140 on the Isle of Man or, more likely, somewhat larger scale.

We won't know any patent details until it's filed or of the deal until it's done but this will happen, according to Tim, within 6 months which, given the length of time LTHs have been patiently waiting would, I suggest, is most definitely near term.

Vas, many thanks for your valuable research. Same also to IV and Barnacle

I've now been through the NCL Digital Diagnostics 5 Year Plan a couple of times and whilst it is a well presented document and there would appear to be a clear role for Bleepa, I cannot get excited by it!

In my view it is not a plan, rather a high level, nice to have vision. For example, what are the actual deliverables? How are they going to be delivered and by whom? What is the budgetary cost and where is that money coming from. It won't be cheap!

The vision has 3 phases or Horizons with a targeted end date of 2030. Horizon 1 which is the only one covered in the Appendices has a 1 year time frame. So, giving them the benefit of the doubt and assuming an end date for Horizon 1 of Dec 2026 how on earth do the expect to deliver that extended wish-list in 18 months? They will undoubtedly engage an outside consultancy to drive the programme, such as PPL, but that won't overcome the bumbling nature of the NHS and protracted decision making. In short, a nice marketing exercise but no more than that

This leads me on to what I see as the biggest problem with the NHS and one of the major reasons why progress with FDBK is worse than watching paint dry, and that is the structure.

With such a large organisation, some form of devolution is necessary. However, much of what they do does not need replicating in every region. They seem most intent on replicating functions and building little/large fiefdoms with the clear mission statement, 'we'll do it our way"!! If you attend your doctor with a hacking cough from which you've been suffering for, let's say, 6 months, the investigation should be similar whether you live in London, the North East or the South West and the process following a diagnosis should also be similar. Is the PPL simulation for London being rolled out across other RHAs? I doubt it because they will all be intent on doing their own thing just to show how smart they are.

The PPL simulation looked an interesting exercise as it involved all London ICBs and multiple other interested functions. One of the major benefits from this exercise should have been to encourage or, better still, force, all ICBs in London to work together on a solution. Yet here we have NCL going off and doing their own thing. Why are they not working together to create a system that works for all? It would speed up the process, reduce costs considerably, enable future integration more readily and, at long last, see the adoption of Bleepa more readily.

Loads,

It is not the responsibility of other investors to convince you. It is your responsibility to assure your good self that you are making a wise investment decision based on your own research. One way of gathering such data is by attending the AGM, by listening and by questioning at such a forum.

I have been invested in IMM since pre first Phase 3 failure, I remain invested and have added significantly in recent months but still remain seriously concerned about our CEO and a perceived lack of progress. I went into the AGM expecting little or no improvement in my scepticism but with a desire/need to learn more. I left feeling much more positive. Why?

Why should I bother sharing with you Loads and others who continue to knock without bothering to dig beneath the surface to try to understand what's actually happening at IMM? Why should any of the other attendees make any effort to provide feedback to folks who expect to be spoon-fed and can't be bothered to make an effort but still continue to knock the company that they claim to have an investment in. All credit to PoorFarmer and indeed Wildbunch if they provide detail on the exchanges during the AGM but let me be quite clear. I can't be bothered with people with your attitude.

However, being a generous type let me leave you with two snippets:

- a P140 patent application will be filed this year covering a wider mechanism of action. This as alluded to in the RNSs of earlier this year. This is expected to include a diagnostic capability for autoimmune diseases and will provide a further 20 years cover. As a consequence, this will make P140 that much more attractive to big-pharma. For obvious reasons details are light at this stage

- a deal will be done this year, although format was not disclosed. Bear in mind that the Avion agreement is solely for Lupus in the USA leaving the rest of the world for that indication and the whole world for others.

If you can make the effort, attend AGMs and ask questions. Surprising what you might learn!!!

OSD, that's the point....he hasn't set out any timelines as you suggest.

Great excitement in RNS and interview of 9th Jan but since then nothing of any real relevance other than RNS of 13th March which was more of the same. No details of what additional attributes of P140 they have discovered just hype around other big deals implying the same could happen with IMM. So where are we???

Doing some prep in readiness for AGM later. Just want to check with others on the following:

RNS 09/09/24 Interim results stated:

- SLE - Ph3 dose range study of P140 CONTINUES preparation with CRO

- CIDP - CIDP IND application CLOSE to submission to FDA

That was over 9 months ago and we have heard nothing since. Am I correct or have I missed something?

CONTINUES and CLOSE are my caps!!

Https://www.share-talk.com/hvo-polb-imm-avct-opti-5-junior-stocks-with-high-stakes-potential-in-2025-2/

Thanks Vas, very interesting.

For a share that has underperformed for so long and with little clarity on the horizon, it is good to see multiple IIs holding a significant position in FDBK. They will need more than good faith to make such investments!!

Some support for the company might see a few more days like yesterday. Listening a domino delivery boy won't help!

Jees mol, what does your deep(er!!) knowledge suggest then?

Good question DC but not a clue!

The RNS of 15th April clearly states leading 'weight management brand' but is that a supplement/food replacement or programme such as WeightWatchers. If the latter not much of a future given competition from the pharmas.

Depends on the formulation but if a snack bar then majors like General Mills and Kelloggs could be of interest given their reach and possible interest in a weight management line. However, being very cynical, I do feel that all big players in the UPF market will only introduce a token gesture as a consequence of investor/market pressure. Their business has been built on sugar and fat and their addictive properties and they're not going to give it up.

Many small players but without the reach and certainly not 'leading'

In short, no idea, so I'll leave it to SOH to surprise us all and, hopefully, the market.

Only product I can find on WalMart with Slimbiome are gummies from a company DietWorks. Don't recollect an RNS about them. Do you know the background?

DC

I hope not! It all looks disgusting and good reason why Americans are so fat.

Also, more seriously, OPTI normally gets a reference on 3rd party products and I don't see on these

One of is is going to be right!!